Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Elevance Health Inc’s stock clocked out at $344.6, down -0.39% from its previous closing price of $345.96. In other words, the price has decreased by -$0.39 from its previous closing price. On the day, 1.86 million shares were traded. ELV stock price reached its highest trading level at $346.375 during the session, while it also had its lowest trading level at $337.535.
Leerink Partners Downgraded its Outperform to Market Perform on July 18, 2025, while the target price for the stock was maintained at $310.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 77596442624 and an Enterprise Value of 72598478848. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.09, and their Forward P/E ratio for the next fiscal year is 12.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 0.373 whereas that against EBITDA is 8.135.
Stock Price History:
The Beta on a monthly basis for ELV is 0.51, which has changed by -0.054650784 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $458.75, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is 2.77%, while the 200-Day Moving Average is calculated to be -3.38%.
Shares Statistics:
It appears that ELV traded 1.73M shares on average per day over the past three months and 1724970 shares per day over the past ten days. A total of 222.04M shares are outstanding, with a floating share count of 221.59M. Insiders hold about 0.29% of the company’s shares, while institutions hold 91.45% stake in the company. Shares short for ELV as of 1764288000 were 3883536 with a Short Ratio of 2.25, compared to 1761868800 on 3479088. Therefore, it implies a Short% of Shares Outstanding of 3883536 and a Short% of Float of 1.7500000000000002.
Dividends & Splits
With its trailing 12-month dividend rate of 6.76, ELV has a forward annual dividend rate of 6.84. Against a Trailing Annual Dividend Yield of 0.019539833. The stock’s 5-year Average Dividend Yield is 1.27. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-12-05 with an ex-dividend date of 2025-12-05. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
. The current assessment of Elevance Health Inc (ELV) involves the perspectives of 20.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $10.45, with high estimates of $11.55 and low estimates of $7.57.
Analysts are recommending an EPS of between $30.17 and $29.67 for the fiscal current year, implying an average EPS of $29.99. EPS for the following year is $26.99, with 22.0 analysts recommending between $29.55 and $24.5.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $49.52B. It ranges from a high estimate of $51.04B to a low estimate of $48.4B. As of. The current estimate, Elevance Health Inc’s year-ago sales were $44.99BFor the next quarter, 11 analysts are estimating revenue of $50.71B. There is a high estimate of $51.84B for the next quarter, whereas the lowest estimate is $49.27B.
A total of 12 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $201.01B, while the lowest revenue estimate was $196.67B, resulting in an average revenue estimate of $198.02B. In the same quarter a year ago, actual revenue was $175.2BBased on 12 analysts’ estimates, the company’s revenue will be $204.35B in the next fiscal year. The high estimate is $208.62B and the low estimate is $197.52B.
